We summarized sensitivity indices (IC50 values adjusted with clinically achievable concentrations of each TKI) generated from Ba/F3 cell experiments and clinical responses in NSCLC patients for each secondary/tertiary mutation together with the EGFR, ALK, and ROS1 driver mutation (Figure 3). This evidence concerns the gene ALK and non-small cell lung carcinoma.